Mozobil (plerixafor)
Customize your policy alerts
Sign up for Anthem Policy CC-0089 alerts
Get alerted when Policy CC-0089 changes without checking for updates manually.
Monitor payer policy activity
Clinical coverage criteria for use of Mozobil (plerixafor) to mobilize hematopoietic stem cells for autologous (and select allogeneic donor) transplantation and for use during development of ex vivo gene therapy; applies to Anthem medical benefit review and prior authorization. Affects providers requesting Mozobil for eligible patients or donors.
Wording and formatting criteria updates; coding reviewed and clarification note for billing added; ICD-10-CM C88.9 replaced with C88.90.
Expanded explicit allowance for use of Mozobil in autologous HSC mobilization as part of development of FDA-approved ex vivo gene therapy (e.g., Zynteglo).
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.